+ All Categories
Home > Health & Medicine > Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Date post: 18-Dec-2014
Category:
Upload: pavel-fedotov
View: 83 times
Download: 0 times
Share this document with a friend
Description:
Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
86
Trans Catheter Treatment of Structural Heart Diseases Tel Aviv Sourasky Medical Center Lev Mendelevich MD
Transcript
Page 1: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Trans Catheter Treatment of Structural Heart Diseases

Tel Aviv Sourasky Medical Center

Lev Mendelevich MD

Page 2: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Echocardiography in Trans Catheter

Treatment of Aortic Stenosis

Page 3: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Aortic Valve Stenosis

Normal Aortic Valve Stenotic Aortic Valve

Page 4: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Types of Aortic Stenosis

Page 5: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Normal Aortic Valve

A normal aortic valve. Both parts were recorded during diastole. A: The long-axis view demonstrates the appearance of a typical normal aortic valve in the closed position. B: The same valve is demonstrated from the short-axis view. Note that, because of shadowing and lateral resolution, the coaptation line between left and noncoronary cusps is not visualized.

Page 6: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Normal Aortic Valve

A normal aortic valve during diastole in the closed position (A) and during systole in the open position (B). Ao, aorta; LA, left atrium; LV, left ventricle; RV, right ventricle.

Page 7: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Valvular Aortic Stenosis – 2 D-Echo

The cusps become thickened and restricted;

Their position is no longer parallel to the aortic walls;

The edges of the cusps point to toward the center of aorta;

No estimation of severity usually by 2 D-echo, but if one of the cusps moves normally – critical aortic stenosis is excluded;

Planimetry is possible on TEE and sometimes on TTE.

Page 8: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

A patient with mild aortic stenosis. LA, left atrium; LV, left ventricle; RV, right ventricle.

Page 9: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

A transesophageal echocardiogram demonstrates the method of direct planimetry of the aortic valve orifice. By carefully adjusting the level of the short-axis plane, the orifice can be visualized in most patients. In this example, severe stenosis was confirmed. AVA, aortic valve area;

Page 10: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Aortic Stenosis – Two-dimensional Echo

Page 11: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Aortic Stenosis Pressure Gradients

1. Peak instantaneous pressure gradient – ΔP (in mm Hg) = 4V²

V – maximal jet velocity (m/s).

2. Mean pressure gradient :

a. Planimetry of the Doppler envelope – VTI of AV velocity;

b. Another method by formula –

ΔPmean = ΔPmax/1.45 + 2 mm Hg

Page 12: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Continuous

wave Doppler

Pressure gradient = 4 x V² = 4 x 5.4² = 117mmHg

Calculation of Aortic Pressure Gradient

Page 13: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Schematic Diagram of Continuity Equation

Page 14: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 15: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Guidelines for Grading Severity of Aortic

Valve Stenosis

Aortic valve area >1.5cm² (>0.9cm²/m²) – mild 1.0 -1.5cm² (0.6 – 0.9 cm²/m²) - moderate <1.0 (<0.6 cm²/m²) - severe Peak pressure gradient < 25mmHg - mild 25-64mmHg - moderate > 64mmHg - severe Peak jet velocity on CW Doppler < 2.5m/sec – mild 2.5-4.0 m/sec – moderate > 4.0m/sec -severe

Page 16: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Echocardiographic Images of Aortic sclerosis (A, B) and Severe Aortic Stenosis (C, D)

Page 17: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Elevated Pressure Gradient - Differential Diagnosis

Sub aortic membrane

Page 18: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Elevated Pressure Gradient - Differential Diagnosis

Hypertrophic obstructive cardiomyopathy

Page 19: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 20: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 21: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Valvular Heart Disease Disease Burden

Nkomo, et al.

Lancet 2006

Prevalence of moderate-severe aortic/mitral valve disease, n=11,091

<45 45-54 55-64 65-74 >74

MR 7.1%

MS 0.2% S 0.2%

AR 1.7%

AS 4.6%

MR 7.1%

AS 4.6%

AR 1.7%

Page 22: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 23: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Operative Mortality for Aortic Valve Surgery

3 to 4 % for AVR

5.5 to 6.8 % for AVR + CABG

7 to 10 % in low volume centers

If > 65 yrs old – 8.8%;

13% in low volume centers

6% in high volume centers

Page 24: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 25: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Aortic Valve Replacement

Page 26: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 27: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 28: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Trans Catheter Aortic Valve Implantation

Page 29: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 30: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 31: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 32: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 33: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 34: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 35: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 36: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Echocardiography in Trans Catheter Treatment of Mitral Regurgitation

Page 37: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Valve

Page 38: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Valves Anatomy

Superior view of the heart showing heart valve anatomy

Page 39: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Normal Mitral Valve Anatomy and Opening

Page 40: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Valve Annulus

Page 41: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Valve Chordae

Page 42: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Valve Commissures

Page 43: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Valve Leaflets

Page 44: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Coaptation Zone

On the atrial surface of the leaflets

exist two zones, one peripheral

smooth or body zone and one

central rough or coaptation zone.

The gently curved coaptation line

between the two leaflets evident

from an atrial view , separates these

two areas.

The rough zone represents the

coaptation surface of the valve.

The coaptation zone is critical to

valve competency, and the depth

and length of coaptation is viewed

as an important assessment of

mitral valve function.

Page 45: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Papillary Muscles

Page 46: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Regurgiatation

Page 47: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 48: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Carpentier Classification

Carpentier’s functional classification

Type I, normal leaflet motion;

Type II, increased leaflet motion (leaflet prolapse);

Type IIIa restricted leaflet motion during diastole and systole;

Type IIIb restricted leaflet motion predominantly during systole

Page 49: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Degenerative Mitral Valve Disease

Degenerative mitral valve disease A, Barlow’s disease B, fibroelastic deficiency

Page 50: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 51: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral regurgitation

Page 52: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Severe MR – Continuous Wave Doppler

Mild MR Severe MR

Page 53: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MR- Mitral Inflow Pulsed Doppler

Mild MR Severe MR

Page 54: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Pulmonary Vein Flow

Normal Severe MR

Page 55: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Regurgitation - Quantification

Proximal isovelocity surface area (PISA)

Vena contracta

Page 56: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Regurgitation - Quantification

Flow convergence (PISA) Vena contracta

Page 57: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 58: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Proximal Isovelocity Surface Area (PISA)

Page 59: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MR - Effective Regurgitant Orifice (ERO)

Page 60: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Regurgitation Severity

When to Consider Surgery

Page 61: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Vena Contracta

Mild MR Severe MR

Page 62: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Operative Mortality for Mitral Valve Surgery

4 to 5 % for MV replacement

2% for MV repair

• If > 80 yrs old +CABG +LV dysfunction or renal failure – 15%

Page 63: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Trans Catheter Mitral Valve Repair By MitraClip

Page 64: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MitraClipTM

קליף פתוח

קליף סגור

Page 65: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 66: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 67: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 68: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 69: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 70: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 71: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 72: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Echocardiography in Trans Catheter

Treatment of Mitral Stenosis

Page 73: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Severity of Mitral Stenosis

MVA (cm2) Mean (mm Hg)

Mild 1.6 - 2.0 < 5

Moderate 1.1 - 1.5 6-10

Severe 1.0 10

Page 74: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Mitral Stenosis - Feasibility of Valvuloplasty

Valve pliable:

-Commissural calcification

- Wilkins/Abascal Score <8

Valve mobility 1-4

Valve Thickening 1-4

Valve Calcification 1-4

Sub-valvular thickening 1-4

MR <2+

No thrombus in LAA

Page 75: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MS Score Index

Mobility

Leaflet thickening

Subvalvular thickening

Calcification

Page 76: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MS Score Index Mobility

Grade 1 Highly mobile valve with leaflet tips only restricted

Grade 2 Leaflet mid and base portions have normal mobility

Grade 3 Valve continues to move forward in diastole, mainly

from the base

Grade 4 No or minimal forward movement from the leaflets

in diastole

Page 77: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MS Score Index Leaflet Thickening

Grade 1 Leaflets near normal in thickness(4 to 5mm)

Grade 2 Mid-leaflets normal, marked thickening of

margins (5 to 8mm)

Grade 3 Thickening extending through the entire leaflet

(5 to 8mm)

Grade 4 Marked thickening of all leaflet tissue (>8mm)

Page 78: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MS Score Index Subvalvular thickening

Grade 1 Minimal thickening just below mitral leaflets

Grade 2 Thickening of chordal structures extending up to

one-third of the chordal length

Grade 3 Thickening extending to the distal third of chords

Grade 4 Extensive thickening and shorting of all chordal

structures extending down to the papillary muscles

Page 79: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MS Score Index Calcification

Grade 1 A single area of increased echo brightness

Grade 2 Scattered areas of brightness confined to leaflet

margins

Grade 3 Brightness extending into the mid-portion of the

leaflets

Grade 4 Extensive brightness throughout much of the

leaflet tissue

Page 80: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

MS Score Index Determining Echo Score

Add the grades from the four

categories.

Patients who score < 8

are more favorable

candidates for balloon

valvuloplasty

Page 81: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Wilkins' Score and Increase in Valve Area

(NHLBI Register Circulation 1992; 85: 448-61)

Page 82: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Inoue Balloon Metallic

Commissurotome

Page 83: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 84: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 85: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases
Page 86: Lev Mendelevich MD — Trans Catheter Treatment of Structural Heart Diseases

Recommended